Caverject en es it fr

Caverject Brand names, Caverject Analogs

Caverject Brand Names Mixture

  • No information avaliable

Caverject Chemical_Formula


Caverject RX_link

Caverject fda sheet

Caverject FDA

Caverject msds (material safety sheet)

Caverject MSDS

Caverject Synthesis Reference

No information avaliable

Caverject Molecular Weight

354.481 g/mol

Caverject Melting Point

115 - 116 oC

Caverject H2O Solubility

26.7 mg/L

Caverject State


Caverject LogP


Caverject Dosage Forms

Liquid; Powder for solution; Solution; Suppository

Caverject Indication

For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Caverject Pharmacology

Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.

Caverject Absorption

The absolute bioavailability of alprostadil has not been determined.

Caverject side effects and Toxicity

Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.

Caverject Patient Information

Caverject Organisms Affected

Humans and other mammals